CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CD19 CAR-T 细胞治疗联合自体干细胞移植治疗复发/难治性 Burkitt 淋巴瘤/白血病：一例病例报告及文献综述
英文原题：CD19 chimeric antigen receptor T-cell therapy following autologous stem cell transplantation against relapsed or refractory Burkitt lymphoma/leukemia: A case report and literature review.
查看英文原题
CD19 chimeric antigen receptor T-cell therapy following autologous stem cell transplantation against relapsed or refractory Burkitt lymphoma/leukemia: A case report and literature review.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
Burkitt淋巴瘤或白血病（BL）是一种高度侵袭性的非霍奇金淋巴瘤。年龄较大（超过60岁）以及存在高危因素（如腹部肿块、血清乳酸脱氢酶水平高、Ann Arbor II-IV期等）通常预示较差的预后。CAR-T 细胞在B细胞白血病和淋巴瘤的治疗中取得了显著成功。在此，我们首次报告了一例61岁高危BL患者，在CAR-T 作为巩固治疗前接受了自体干细胞移植（ASCT）桥接治疗。我们的研究结果表明，ASCT联合CAR-T 治疗BL是安全且可行的。
展开英文摘要原文
Burkitt lymphoma or leukemia (BL) is a highly aggressive non-Hodgkin lymphoma. Older age (over 60 years old) and the presence of high-risk factors (such as abdominal mass, high levels of the serum lactic dehydrogenase, Ann Arbor stage II-IV and so on) usually predict a poorer outcome. Chimeric antigen receptor T cells (CART) have achieved remarkable success in the treatment of B-cell leukemia and lymphoma.
Here, for the first time, we report a 61-year-old, high-risk BL patient with autologous stem cell transplantation (ASCT) bridging therapy prior to CART as consolidation therapy.
Our findings demonstrate that the combination of ASCT and CART for BL is safe and feasible.
论文信息
- 作者
- Ye M、Gao L、Wang T、Yu J、Gui J、Yang J
- 单位
- Department of Hematology, The First Affiliated Hospital of Naval Medical University, Shanghai, China.China
- 文献类型
- 病例报告
- 期刊
- Frontiers in oncology2022
- 原文标识
- PubMed 36353549 · DOI 10.3389/fonc.2022.932254
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →